PMID

Data

Article Title

Organization

Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.

Bristol-Myers Squibb

Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.

Universit£

Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.

Johnson & Johnson

Discovery of cyclic amine-substituted benzoic acids as PPARa agonists.

Kyorin Pharmaceutical

Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.

F. Hoffmann-La Roche

Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.

Novartis Institutes For Biomedical Research

Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.

Novo Nordisk

Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.

Ligand Pharmaceuticals

Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.

Kyorin Pharmaceutical

Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPAR?)-selective agonists.

Okayama University

Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

Virginia Commonwealth University